A long-term extension study found that adjunctive vagus nerve stimulation (VNS) had a durable benefit in patients with treatment-resistant major depression over 24 months.
A long-term extension study found that adjunctive vagus nerve stimulation (VNS) had a durable benefit in patients with treatment-resistant major depression over 24 months.
The US Food and Drug Administration has approved Proliv™Rx, a novel at-home neuromodulation therapy as adjunctive treatment for adults with major depressive disorder (MDD).
The US Food and Drug Administration has approved Proliv™Rx, a novel at-home neuromodulation therapy as adjunctive treatment for adults with major depressive disorder (MDD).
A new multi-site study suggests that while delay discounting is elevated in patients with remitted MDD, it neither changes after antidepressant medication discontinuation nor predicts subsequent depressive relapse.
A new multi-site study suggests that while delay discounting is elevated in patients with remitted MDD, it neither changes after antidepressant medication discontinuation nor predicts subsequent depressive relapse.
An analysis from the multicenter PRONIA consortium reports that integrated peripheral inflammatory markers and whole-brain gray matter volumes can distinguish early-stage depression from psychosis.
An analysis from the multicenter PRONIA consortium reports that integrated peripheral inflammatory markers and whole-brain gray matter volumes can distinguish early-stage depression from psychosis.
The US Food and Drug Administration (FDA) has approved the first at-home transcranial direct current stimulation (tDCS) device for the treatment of moderate to severe major depressive disorder (MDD).
The US Food and Drug Administration (FDA) has approved the first at-home transcranial direct current stimulation (tDCS) device for the treatment of moderate to severe major depressive disorder (MDD).
Adults with depression experienced similar treatment effects from asynchronous, message-based psychotherapy (MBP) and video-based psychotherapy (VBP), according to study results.
Adults with depression experienced similar treatment effects from asynchronous, message-based psychotherapy (MBP) and video-based psychotherapy (VBP), according to study results.
The US Food and Drug Administration (FDA) has approved lumateperone (CAPLYTA®) as an adjunctive therapy with antidepressants for the treatment of major depressive disorder (MDD) in adults.
The US Food and Drug Administration (FDA) has approved lumateperone (CAPLYTA®) as an adjunctive therapy with antidepressants for the treatment of major depressive disorder (MDD) in adults.
A secondary analysis of the 2019 PANDA trial found that sertraline improved core symptoms of depression at as early as 2 weeks of treatment, suggesting a faster-acting benefit than previously thought.
A secondary analysis of the 2019 PANDA trial found that sertraline improved core symptoms of depression at as early as 2 weeks of treatment, suggesting a faster-acting benefit than previously thought.
Early exposure to lead, particularly in the third trimester of pregnancy, was associated with a higher risk of major depressive disorder and anxiety symptoms in later life, according to cohort study results.
Early exposure to lead, particularly in the third trimester of pregnancy, was associated with a higher risk of major depressive disorder and anxiety symptoms in later life, according to cohort study results.
According to a recent post hoc analysis, esmethadone (REL-1017) may be an effective adjunctive treatment for patients with major depressive disorder (MDD) and antidepressant tolerance/tachyphylaxis (AT).
According to a recent post hoc analysis, esmethadone (REL-1017) may be an effective adjunctive treatment for patients with major depressive disorder (MDD) and antidepressant tolerance/tachyphylaxis (AT).
Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN
Featuring Andrew Penn, MS, PMHNP...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
